Restricted accessLetterFirst published online 2018-06
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design,Definitions,and Ongoing Challenges for Child and Adolescent Psychopharmacology Research
DunlopBW, ThaseME, WunCC, FaryyadR, Guicio-PabiaCJ, MusqnungJ, NinanPT: A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: The importance of academic sites. Neuropsychopharmacology, 37:2830–2836, 2012.
2.
EmslieGJ, KennardBD, MayesTL, NakoneznyPA, MooreJ, JonesJM, FoxwellAA, KingJ: Continued effectiveness of relapse prevention cognitive-behavioral therapy following fluoxetine treatment in youth with major depressive disorder. J Am Acad Child Adolesc Psychiatry, 54:991–998, 2015.
WalkupJT: Antidepressant efficacy for depression in children and adolescents: Industry-and NIMH-funded studies. Am J Psychiatry, 174:430–437, 2017.
5.
WeihsKL, MurphyW, AbbasR, ChilesD, EnglandRD, RamakerS, WajsbrotDB: Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol, 28:36–46, 2018.
